BCMA DASH CAR-T cells therapy (Hrain Biotechnology)

N/A

Report date: 2024/04/10 17:59:40

Base Information

Drug NameBCMA DASH CAR-T cells therapy (Hrain Biotechnology)
Drug Alias NameHR017
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A